Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01

open access

Page views 313
Article views/downloads 4417
Get Citation

Connect on Social Media

Connect on Social Media

Gaucher disease – recommendations concerning diagnosis, treatment and monitoring

Piotr Hasiński1, Mirosław Bik-Multanowski2, Magdalena Koba-Wszędobył3, Mieczysław Walczak4, Marek Bubnowski5, Agnieszka Milewska-Kranc6, Andrzej Smyk7, Maciej Machaczka89
DOI: 10.1016/j.achaem.2017.10.001
Acta Haematol Pol 2017;48(4):222-261.


The following recommendations are the first complete document concerning the diagnosis, treatment and monitoring of Gaucher disease (GD) in Poland. GD is a rare, genetically determined storage disorder, involving deficiency or absence of glucocerebrosidase activity, a lysosomal enzyme that digests glucosylceramide. Glucosylceramide excessively accumulates in the monocyte-macrophage system (Gaucher cells), which in turn accumulate primarily in the bone marrow, spleen and liver. In the most severe forms of the disease, central nervous system is also involved. There are three clinical types of Gaucher disease, and the primary criteria for their differentiation is the involvement of the central nervous system, and the rate of symptom progression. The least severe and most common is type 1 GD, characterised mainly by hematological manifestations, such as thrombocytopenia and anemia, splenomegaly, hepatomegaly and skeletal involvement (bone pain, bone deformities, pathological fractures). Types 2 and 3 GD involve various central nervous system manifestations. Diagnosis of Gaucher disease is difficult, particularly in individuals from families without prior GD history. Gaucher disease is characterised by a heterogenic disease course and is rarely considered in differential diagnosis. This presents a major problem, as correct diagnosis and treatment implementation are often delayed by many years. This can lead to serious complications and even premature death of the patient. Currently, the primary therapeutic approach is an enzyme replacement therapy, involving an intravenous administration of recombinant glucocerebrosidase. Treatment of mild and moderate forms of the disease also includes an oral therapy which inhibits the production of glucocerebroside.

Article available in PDF format

View PDF (Polish) Download PDF file